Poland· PL-100492670
Eylea
A aflibercept product containing afliberceptum, registered in Poland by Bayer AG. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Aflibercept is registered in 11 of 19 countries.
Countries holding a registration under ATC S01LA05 (aflibercept), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Aflibercept · ATC S01LA05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Afliberceptum
- Manufacturer
- Bayer AG
- Country
- Poland (PL)
- ATC code
- S01LA05
- ATC class
- Aflibercept
- Defined daily dose
- 0.018 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin04057598023047
- gtin04057598033756
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Aflibercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenEylea 114,3 mg/ml Injektionsvätska, lösningBayer AG
- CzechiaEYLEABayer AG, Leverkusen
- SpainEYLEA 114,3 MG/ML SOLUCION INYECTABLEBayer Ag
- FranceEYLEA 114,3 mg/mL, solution injectableBAYER AG (ALLEMAGNE)
- IrelandEylea 114.3 mg/ml solution for injectionBayer AG
- IcelandEyleaBayer AG*
- BelgiumEylea 114.3 mg/mlBayer
- NorwayEyleaBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Vgenfli
- Iceland · Afiveg, Afqlir
- Liechtenstein · Afiveg, Afqlir
- Norway · Afiveg, Afqlir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ac38d2ac-aff6-4758-9bbf-491b32902b81 GET /v1/drugs/ac38d2ac-aff6-4758-9bbf-491b32902b81?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "114,3 mg/ml",
"packaging": "04057598023047 ¦ Rpz ¦ EU/1/12/797/003 ¦ 153005\n1 igła z filtrem ¦ 1 fiol. \n04057598033756 ¦ Rpz ¦ EU/1/12/797/004 ¦ 166275\n1 amp.-strzyk.",
"substance": "Afliberceptum 114.3 mg/ml",
"common_name": "Afliberceptum",
"pl_product_id": "100492670",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about aflibercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.